{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-008337","form_type":"8-K","ticker":"NRXP","cik":"0001719406","company_name":"NRX Pharmaceuticals, Inc.","filed_at":"2024-05-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.726492+00:00","generated_at":"2026-06-01T21:29:37.635419+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"NRx Pharma Q1 net loss narrows to $6.5M; signs $7.5M debt term sheet to replace toxic debt","bullets":["Net loss improved 41% YoY to $6.5M, from $11.0M; R&D spend down to $1.7M.","Cash and equivalents $1.3M as of March 31, 2024; additional $3.3M from equity post-quarter.","Signed non-binding term sheet for $7.5M debt to replace toxic debt, with potential total up to $30M.","Plans to file NDA for NRX-101 in bipolar depression with akathisia risk and for IV ketamine (HTX-100) by July 2024.","Hope Therapeutics spinout planned; term sheets received from anchor investors for $60M investment."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-008337","json":"https://secwatch.observer/filing/0001558370-24-008337.json","markdown":"https://secwatch.observer/filing/0001558370-24-008337.md","text":"https://secwatch.observer/filing/0001558370-24-008337.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719406/000155837024008337/0001558370-24-008337-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719406/000155837024008337/nrxp-20240514x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T21:29:37.635419+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8a127dd03560ae405cd6b636d2faac04a2357991","claim":"NRX Pharmaceuticals, Inc. reported financial results for quarter ended March 31, 2024.","evidence_excerpt":"NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical-stage biopharmaceutical company, today announced its financial results for the quarter ended March 31, 2024, and provided a business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1719406/000155837024008337/0001558370-24-008337-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"8dd91d88767e55d381df106b490887eb189b049c","claim":"NRX Pharmaceuticals, Inc. reported financial results for first quarter ending March 31, 2024.","evidence_excerpt":"On May 14, 2024, NRx Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing its financial results for the first quarter ending March 31, 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1719406/000155837024008337/0001558370-24-008337-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ending March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}